

Title: Patient perspectives and experiences of preventive treatments and self-injectable devices for migraine: a focus group study

Journal: *The Patient*

Authors: Jaein Seo, Charlie A. Smith, Caitlin Thomas, Tommi Tervonen, Asha Harandeen, Janet H. Ford, Virginia L. Stauffer, Robert A. Nicholson, Kevin Harrison Duffy, Antje Tockhorn-Heidenreich

Corresponding author: Jaein Seo, Evidera. E-mail: Jaein.Seo@evidera.com.

Online Resource 6: Ranking of treatment characteristics by each focus group

US01 (EM, n=5)	Number of days with migraine	1st
	Severity of migraine	2nd
	Concentration problems	3rd
	Time it takes to inject medicine	3rd
	Easy to hold	5th
	Pressing the button/plunger	6th
	Dose confirmation window	7th
US02 (CM, n=5)	Less frequent migraine	1st
	Less intense migraine	2nd
	Size of the device	3rd
	Design, appearance of the device	4th
	Needle protection	5th
	Disposal	6th
US03 (CM, n=4)	Vision problem of migraine	1st
	Portability	2nd
	Time it takes to inject	3rd
	Disposal/environmental concerns	4th
	Dose confirmation window	5th
	Needle visibility	6th
	Pressing button	7th
UK01 (EM, n=5) (CM, n=1)	Severity of headaches	1st
	Frequency of headaches	2nd
	Nausea	3rd
	Fatigue	4th
	Memory problems	5th
	Time for dose completion	5th
	Type of device	7th
UK02 (CM, n=3) (EM, n=1)	Reduction in migraine severity	1st
	Reduction in migraine frequency	1st
	Side effects	3rd
	Loss of efficacy of acute migraine treatment	4th
	Type of device (autoinjector vs. prefilled syringe)	5th
	Time for injection to complete	6th
	Need to pinch skin	7th
UK03 (CM, n=4) (EM, n=3)	Reduce frequency of migraine episodes	1st
	Reduced duration of migraine episodes	2nd
	Frequency of injection	3rd
	Number of steps during injection	4th
	Safety mechanics of device	5th
	Portability of device	6th
DE01 (EM, n=5)	Decrease frequency of migraine	1st
	Decrease intensity of migraine	2nd
	Maintenance of functionality/being able to work	2nd
	Frequency of application	4th
	Disposal/waste	5th
	Device handling	6th
	Injection site pain	7th
	Length of injection	8th
Side effects	9th	
DE02 (CM, n=1) (EM, n=4)	Reduction of migraine frequency	1st
	Few side effects (psychological effects, weight gain)	2nd
	Reduction in intensity/severity of migraine	3rd
	Creates normality (no burden of disease)	4th
	Good information about the drug	5th
	Easy and safe use (syringe, pen)	6th
	Reimbursement / access / bureaucracy	7th
	Size and weight of applicator	8th
	Handling, practicality	9th
	Disposal/waste	10th
DE03 (CM, n=4) (EM, n=2)	Less migraine attacks (lower frequency)	1st
	Few side effects	2nd
	Participation in social life possible	2nd
	Lower intensity of pain in migraine	4th
	Faster onset, easy on and off	5th
	Frequency of administration	6th
	Easy and self-explanatory application	7th
	Pain when applied	8th
	Easy explanation, description	9th
	Multiple use (refill)	10th
	Storage/disposal	11th